ArticleTherapeutic advances in medical oncology2020

Olaparib is effective for recurrent urothelial carcinoma with BRCA2 pathogenic germline mutation: first report on olaparib response in recurrent UC.

Hong Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.